IDYA Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

34.020

Open

33.390

VWAP

33.00

Vol

846.00K

Mkt Cap

3.00B

Low

32.510

Amount

28.00M

EV/EBITDA(TTM)

Total Shares

88.00M

2.00B

EV/OCF(TTM)

P/S(TTM)

14.00

IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). IDE196, a small-molecule protein kinase C (PKC) inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397 is its small-molecule methionine adenosyltransferase 2a (MAT2A) inhibitor. IDE275 (GSK959) Werner Helicase (WRN) inhibitor for patients having tumors with MSI-High. IDE161 (PARG) is a small-molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor. IDE705 is a small-molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small-molecule inhibitor of poly-(ADP-ribose) polymerase (PARP).

Events Timeline

(ET)

2026-01-11

14:50:00

IDEAYA Biosciences Updates 2026 Corporate Objectives

2025-12-11 (ET)

2025-12-11

06:10:00

Ideaya Completes Enrollment of 435 Patients in Clinical Trial

2025-12-10 (ET)

2025-12-10

06:10:00

Ideaya Biosciences Submits IDE574 IND Application, Plans Phase 1 Trial in Q1 2026

2025-12-09 (ET)

2025-12-09

07:10:00

Ideaya Biosciences Terminates Collaboration Agreement with GSK

News

7.0

01-11PRnewswire

IDEAYA Biosciences Updates 2026 Corporate Objectives at J.P. Morgan Conference

7.0

01-11Newsfilter

IDEAYA Biosciences Updates 2026 Strategic Objectives, Plans to Advance Four Registrational Trials

7.0

01-11Yahoo Finance

IDEAYA Biosciences Outlines 2026 Corporate Objectives and Clinical Progress

8.0

01-06NASDAQ.COM

IDYA Options Offer Attractive Discounts and Yield Boosts

1.0

01-05PRnewswire

IDEAYA to Participate in 44th Annual J.P. Morgan Healthcare Conference

8.0

2025-12-30NASDAQ.COM

IDEAYA Biosciences Options Volume Surges to 9,708 Contracts

15 Analyst Rating

Wall Street analysts forecast IDYA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IDYA is 49.86 USD with a low forecast of 30.00 USD and a high forecast of 79.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

13 Buy

2 Hold

0 Sell

Strong Buy

Current: 0.000

Low

30.00

Averages

49.86

High

79.00

Current: 0.000

Low

30.00

Averages

49.86

High

79.00

RBC Capital

NULL

Outperform

maintain

$41 -> $45

AI Analysis

2026-01-21

Reason

RBC Capital

Price Target

$41 -> $45

AI Analysis

2026-01-21

maintain

NULL

Outperform

Reason

RBC Capital raised the firm's price target on Ideaya Biosciences to $45 from $41 and keeps an Outperform rating on the shares. The firm updated models for several biotech companies after meeting with managements.

UBS

assumed

$50

2026-01-07

Reason

UBS

Price Target

$50

2026-01-07

assumed

Reason

UBS assumed coverage of Ideaya Biosciences (IDYA) with a Buy rating and $50 price target. as the analyst initiated or assumed coverage on 22 small-to-mid cap biotech names. After a rough period, biotech fundamentals are now inflecting, contends the analyst, who expects investor confidence to recover and sees this positioning biotech for strong performance in 2026. Among the group, top picks include Apogee Therapeutics (APGE), Cogent Biosciences (COGT), Kodiak Sciences (KOD), Ideaya Biosciences, Inventiva (IVA), SAB Biotherapeutics (SABS) and Ventyx Biosciences (VTYX), which the analyst highlights as having key upcoming catalysts, de-risked best-in-class portfolios, strong data, and broader pipelines.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for IDYA

Unlock Now

Valuation Metrics

The current forward P/E ratio for IDEAYA Biosciences Inc (IDYA.O) is -9.02, compared to its 5-year average forward P/E of -11.40. For a more detailed relative valuation and DCF analysis to assess IDEAYA Biosciences Inc 's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-11.40

Current PE

-9.02

Overvalued PE

-6.69

Undervalued PE

-16.11

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-6.05

Current EV/EBITDA

-4.83

Overvalued EV/EBITDA

-2.43

Undervalued EV/EBITDA

-9.66

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

90.76

Current PS

124.28

Overvalued PS

185.09

Undervalued PS

-3.57

Financials

AI Analysis

Annual

Quarterly

Whales Holding IDYA

Sofinnova Investment, Inc.

Deerfield Management Company, L.P.

Baker Bros. Advisors LP

General American Investors Company, Inc.

Trading Trends

People Also Watch

Frequently Asked Questions

What is IDEAYA Biosciences Inc (IDYA) stock price today?

The current price of IDYA is 32.99 USD — it has decreased -1.96 % in the last trading day.

What is IDEAYA Biosciences Inc (IDYA)'s business?

What is the price predicton of IDYA Stock?

Wall Street analysts forecast IDYA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IDYA is49.86 USD with a low forecast of 30.00 USD and a high forecast of 79.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is IDEAYA Biosciences Inc (IDYA)'s revenue for the last quarter?

IDEAYA Biosciences Inc revenue for the last quarter amounts to 208.00M USD, decreased % YoY.

What is IDEAYA Biosciences Inc (IDYA)'s earnings per share (EPS) for the last quarter?

IDEAYA Biosciences Inc. EPS for the last quarter amounts to 1.33 USD, decreased -321.67 % YoY.

How many employees does IDEAYA Biosciences Inc (IDYA). have?

IDEAYA Biosciences Inc (IDYA) has 131 emplpoyees as of January 30 2026.

What is IDEAYA Biosciences Inc (IDYA) market cap?

Today IDYA has the market capitalization of 3.00B USD.

IDYA Overview

IDYA Overview

Events Timeline

News

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Whales Holding IDYA

Trading Trends

People Also Watch

Frequently Asked Questions

What is IDEAYA Biosciences Inc (IDYA) stock price today?

What is IDEAYA Biosciences Inc (IDYA)'s business?

What is the price predicton of IDYA Stock?

What is IDEAYA Biosciences Inc (IDYA)'s revenue for the last quarter?

What is IDEAYA Biosciences Inc (IDYA)'s earnings per share (EPS) for the last quarter?

How many employees does IDEAYA Biosciences Inc (IDYA). have?

What is IDEAYA Biosciences Inc (IDYA) market cap?